Baricitinib to help reduce HIV in the brain
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This Phase 2 study tests baricitinib to see if it can lower HIV activity in the brain (CNS) for people already on stable HIV treatment. If you have well-controlled HIV in your blood, this trial looks for additional benefit inside the nervous system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old
- Your HIV is well controlled on continuous ART: viral load below 200 copies/mL for at least 12 months
- Your CD4 count is above 350 for at least 12 months while on treatment
- You are not pregnant and not breastfeeding; if you can become pregnant, you must use effective birth control
- You have no major blood count problems on screening (low white cells, low hemoglobin, or low platelets)
- You do not currently have certain serious infections or recent sick illnesses (including untreated tuberculosis and active herpes symptoms)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if adding the drug baricitinib to your regular HIV treatment can reduce the amount of virus hiding in your body, which might help control HIV better or even lead to a cure.
This Phase 2 study looks at whether lowering inflammation can help improve depression symptoms in adults living with HIV. You may be able to join if your HIV is well controlled and you are currently experiencing major depression (or a certain type of bipolar depression).
This trial tests if two drugs, baricitinib and sirolimus, can help control HIV after stopping standard antiretroviral therapy (ART). It aims to see if these immune treatments allow patients to maintain viral suppression without daily pills.
This early-stage trial tests whether two drugs work together to reduce hidden HIV in your body while you're on stable HIV treatment. The goal is to understand how safe the combination is and whether it helps clear dormant HIV cells.
This trial tests if baricitinib, a pill that calms the immune system, can slow down or delay the onset of type 1 diabetes in children and adults who are at high risk. It is for people whose blood sugar is already starting to rise but who do not yet need insulin.
This trial tests if baricitinib, an anti-inflammatory drug, can help people with bleeding in the brain from a head injury. It is for adults with moderate to severe traumatic brain injury who are not immediately having surgery.
Hear when a new Human Immunodeficiency Virus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.